THANK YOU FOR YOUR SITE'S PARTICIPATION IN THE SHIMMER STUDY, A PHASE 2 RESEARCH STUDY ON A POTENTIAL NEW TREATMENT FOR DEMENTIA WITH LEWY BODIES (DLB).

SHIMMER
COG1201

PATIENT POPULATION

50-85

Adults ages 50 to 85, inclusive.

120 participants

Up to 120 participants will be enrolled in the study.

STUDY PURPOSE

The SHIMMER study is evaluating the study drug, CT1812, in up to 120 adults who have been diagnosed with mild to moderate Dementia with Lewy Bodies (DLB).

Participants will be randomly assigned to 1 of the 3 groups in this study:

GROUP 1
Will take 100 mg of CT1812
(2 capsules) once daily

GROUP 2
Will take 300 mg of CT1812
(2 capsules) once daily

GROUP 3
Will take the placebo
(2 capsules) once daily

Study Duration

The total duration of participation in the study is approximately 8 months, including screening. Each participant and caregiver will be required to attend a total of 12 site visits throughout the duration of this study.

Each participant and caregiver will take part in a Screening Visit up to 42 days prior to receiving your first dose, followed by a Double-blind Treatment Period of 182 days (approximately 6 months) and a Follow-up Visit at Day 210.

Study Medication

The study drug, CT1812, is being investigated for the treatment of DLB. The purpose of this research study is to learn about the safety and effectiveness of CT1812 and how well the body tolerates a once-a-day oral dose of CT1812. The study will also test how well CT1812 will treat mild to moderate DLB.

CT1812 is a capsule taken every morning by mouth with food. This study drug will be compared to a placebo.

Compensation for time and travel may be provided to study participants.



CONTACT INFORMATION

www.shimmerDLBstudy.com
859-323-1331

SCAN ME